Skip to main content


Biotech Stock Mailbag: Enanta, Vanda, Pharmacyclics, Top 2014 Stock Catalysts

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Grading the Twitterverse's 2013 Biotech Stock Picks

Some of your predictions were spot on, others not so much.

Leaders of <I>TheStreet's</I> Drug Approval Contest

This group of contestants have nearly perfect records picking FDA and European drug approvals.

The Next Big Thing In Biotech: Decision Week

Ziopharm, AP Pharma and Biogen Idec will headline a very big week of approval decisions, Adam Feuerstein, Sr. Columnist at TheStreet, tells Gregg Greenberg.

Best And Worst FDA Drug Approval Stocks of 2013

Contestants in TheStreet's FDA Drug Approval Contest think well of Sarepta, Navidea and Biogen, less so about Arena, Aveo and Delcath.

Breaking News

Twitter Stock Leaps As Elon Musk Adds More Equity To $44 Billion Takeover Bid, Closes Tesla Margin Loan

Elon Musk has closed out his margin loans, linked to Tesla shares, and pledged another $6.25 billion in equity to fund his $44 billion takeover of the social media website.

Nvidia Stock: Investors Are Buying the Dip. Where From Here?

Nvidia stock is being bought on the dip. Here's how traders should approach it now.

Macy's Stock Soars On Q1 Earning Beat, 2022 Profit Forecast Boost As Shoppers Defy Inflation Gloom

"While macroeconomic pressures on consumer spending increased during the quarter, our customers continued to shop," said CEO Jeff Gennette.

Broadcom Agrees to Buy VMware in $61 Billion Cash-and-Stock Cloud Software Deal

"Combining our assets and talented team with Broadcom's existing enterprise software portfolio creates a remarkable enterprise software player," said VMware CEO Raghu Raghuram.